4.4 Article

Comparison of Outcomes in Patients Aged <75, 75 to 84, and ≥85 Years With ST-Elevation Myocardial Infarction (from the ACTION Registry-GWTG)

Journal

AMERICAN JOURNAL OF CARDIOLOGY
Volume 106, Issue 10, Pages 1382-1388

Publisher

EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2010.07.008

Keywords

-

Funding

  1. Schering-Plough Corporation, Whitehouse Station, New Jersey
  2. Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, New York, New York

Ask authors/readers for more resources

ST-segment elevation myocardial infarction (STEMI) is common in older adults and has high age-related mortality. We describe contemporary STEMI care using the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Network Registry Get With The Guidelines (ACTION-GWTG) database. Patients with STEMI (n = 30,188) from 285 ACTION-GWTG sites from January 1, 2007 to June 30, 2008 were grouped by age (<75, 75 to 84, and >= 85 years) to compare baseline characteristics, reperfusion, and in-hospital outcomes. In this population, 79.7% (24,070) were <75 years old, 14.2% (4,273) were 75 to 84 years old, and 6.1% (1,845) were >= 85 years old (the oldest old). Compared to younger patients, the oldest-old patients (median age 88 years, inter-quartile range 86 to 91) were more often women, had more hypertension, and end-organ co-morbidity (heart failure and stroke, p < 0.0001 for all). More than 42% of the oldest old were also cited as having contraindications to reperfusion, but with absolute or relative contraindications noted in only 10%, and patient preference was the most common reason indicated (45%). Even in reperfusion-eligible patients, the oldest old were less likely to receive it. Although patients who received reperfusion had better outcomes than those who did not, this was significant only for younger patients (<75 years old, odds ratio 0.58, confidence interval 0.40 to 0.84). In conclusion, >42% of the oldest old have reported contraindications to reperfusion, with neither mortality benefit nor harm in those who receive it. Disparities in process of care and co-morbidity may explain these observational findings. Whether efforts to optimize patient selection and initiate reperfusion therapy can improve outcomes in the oldest old with STEMI is unknown. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;106:1382-1388)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available